{Reference Type}: Journal Article
{Title}: Biomarkers of neurodegeneration in isolated and antidepressant-related rapid eye movement sleep behavior disorder.
{Author}: Biscarini F;Pizza F;Vandi S;Incensi A;Antelmi E;Donadio V;Ferri R;Liguori R;Plazzi G;
{Journal}: Eur J Neurol
{Volume}: 31
{Issue}: 6
{Year}: 2024 Jun 26
{Factor}: 6.288
{DOI}: 10.1111/ene.16260
{Abstract}: <B>OBJECTIVE: </B>This study compared the features of isolated rapid eye movement (REM) sleep behavior disorder (iRBD) and antidepressant-related REM sleep behaviour disorder (RBD) with the aim of highlighting markers that might distinguish the two entities.<BR><B>METHODS: </B>The observational cohort study included RBD patients with and without antidepressant use (antiD+ and antiD- patients, respectively), without cognitive impairment and parkinsonism. Clinical features of RBD, subtle motor and non-motor symptoms of parkinsonism, sleep architecture, REM atonia index, dopamine transporter-single photon emission computed tomography (DAT-SPECT) and skin biopsies for the intraneuronal alpha-synuclein (α-syn), were evaluated in the baseline work-up.<BR><B>RESULTS: </B>Thirty-nine patients, 10 antiD+ and 29 antiD-, were included. AntiD+ patients (more frequently female) reported more psychiatric symptoms, less violent dream enactment, and less frequent hyposmia. Dermal α-syn was detected in 93.1% of antiD- versus 30% of antiD+ patients (p = 0.00024). No differences appeared in other motor and non-motor symptoms, Movement Disorder Society-Unified Parkinson's Disease Rating Scale part III score, DAT-SPECT, or polysomnographic features.<BR><B>CONCLUSIONS: </B>Patients with antidepressant-related RBD have clinical and neuropathological features suggesting a lower risk of evolution than those with iRBD.